User:Ajeffs

From OpenWetWare

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
<!--Back to [[Eccles Lab]]  |  [[User:Ajeffs/Notebook | Notebook]] <html><a href="/wiki/User:Ajeffs/Notebook"><img src="/images/9/94/Report.png" border="0" /></a></html>
<!--Back to [[Eccles Lab]]  |  [[User:Ajeffs/Notebook | Notebook]] <html><a href="/wiki/User:Ajeffs/Notebook"><img src="/images/9/94/Report.png" border="0" /></a></html>
-->
-->
-
[[User:Ajeffs/Notebook | Notebook]] <html><a href="/wiki/User:Ajeffs/Notebook"><img src="/images/9/94/Report.png" border="0" /></a></html>
+
<!-[[User:Ajeffs/Notebook | Notebook]] <html><a href="/wiki/User:Ajeffs/Notebook"><img src="/images/9/94/Report.png" border="0" /></a></html>
-
 
+
-->
<font size="4">Aaron Jeffs</font size>
<font size="4">Aaron Jeffs</font size>

Revision as of 17:35, 18 January 2011

<!- Notebook --> Aaron Jeffs

Department of Pathology
Dunedin School of Medicine
University of Otago
Dunedin
New Zealand

aaron.jeffs at otago.ac.nz

Contents

Research Interests

  • Cancer genetics
  • Oncogenomics

Education

  • PhD (Otago) 2001.
  • MSc Hons (Canterbury) 1994.

Publications

Peer-reviewed

  1. Jeffs AR, Glover AC, Slobbe LJ, Wang L, He S, Hazlett JA, Awasthi A, Woolley AG, Marshall ES, Joseph WR, Print CG, Baguley BC, and Eccles MR. . pmid:20041153. PubMed HubMed [Jeffs-2009]
  2. Jenkins ZA, van Kogelenberg M, Morgan T, Jeffs A, Fukuzawa R, Pearl E, Thaller C, Hing AV, Porteous ME, Garcia-Miñaur S, Bohring A, Lacombe D, Stewart F, Fiskerstrand T, Bindoff L, Berland S, Adès LC, Tchan M, David A, Wilson LC, Hennekam RC, Donnai D, Mansour S, Cormier-Daire V, and Robertson SP. . pmid:19079258. PubMed HubMed [Jenkins-2008]
  3. Dziarmaga A, Hueber PA, Iglesias D, Hache N, Jeffs A, Gendron N, Mackenzie A, Eccles M, and Goodyer P. . pmid:16735463. PubMed HubMed [Dziarmaga-2006]
  4. M. Futschik, A.Jeffs, S.Pattison, N.Kasabov, M.Sullivan, A.Merrie, A.Reeve (2002). Gene expression profiling of metastatic and non-metastatic colorectal cancer cell-lines. Genome Letters 1(1):26-34. [Futschik-2002]
  5. Jeffs AR, Wells E, and Morris CM. . pmid:11550282. PubMed HubMed [Jeffs-2001]
  6. Benjes SM, Millow LJ, Jeffs AR, Sowerby SJ, Reeve AE, and Morris CM. . pmid:10534772. PubMed HubMed [Benjes-1999]
  7. Jeffs AR, Benjes SM, Smith TL, Sowerby SJ, and Morris CM. . pmid:9536079. PubMed HubMed [Jeffs-1998]
  8. Morris C, Jeffs A, Smith T, McDonald M, Board P, Kennedy M, and Fitzgerald P. . pmid:8637725. PubMed HubMed [Morris-1996]
All Medline abstracts: PubMed HubMed

Non-peer-reviewed

  1. Robson, Ewan, Jeffs, Aaron, and Eccles, Michael. Off-target response to decoy oligodeoxynucleotide treatment. Available from Nature Precedings http://hdl.handle.net/10101/npre.2008.2281.1 (2008) [Robson-2008]

Funding

2010

  • "MicroRNA function in melanoma", The Healthcare Otago Charitable Trust, October 2010 for 1 year ($14,127). A. Jeffs.
  • "Urinary microRNA: a novel marker of acute kidney injury", University of Otago Research grant, October 2010 for 1 year ($44,000). R. Walker (PI), A. Jeffs, Z. Endre, and J. Pickering.
  • "Can isoforms of the p53 tumour suppressor cause cancer?", Health Research Council of New Zealand, June 2010 for 36 months ($1,158,492). A. Braithwaite (PI), N. Hung, A. Jeffs, and T. Slatter.
  • "A novel gene that modifies melanoma invasive potential", Dunedin School of Medicine Dean's Bequest Fund, June 2010 for 1 year ($5420). A. Jeffs.
  • "Grant-in-aid for QMB Cancer meeting 2010", Maurice & Phyllis Paykel Trust ($4000). A. Jeffs & M. Eccles.
  • Professional Development Award to attend the AMATA10 meeting, Hobart, Australia, Genesis Oncology Trust ($1,957). A. Jeffs.
  • Dunedin School of Medicine Travel Grant to attend the AMATA10 meeting, Hobart, Australia ($885). A.Jeffs.

2009

  • "Genome instability in melanoma", NZ Lottery Grants Board (Application 278243), 01/01/2010 for 2 years ($116,328). A. Jeffs (PI), M. Eccles, and B. Baguley.
  • "The molecular basis of melanoma: integrating microRNA expression and DNA copy number variation to define clinically relevant markers of invasion and prognosis", The HealthCare Otago Charitable Trust ($10,434), 01/02/10 for 1 year. A. Jeffs.



Personal tools